A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

CoreLink Surpasses 5,000 Entasis SI Joint Fusion Implantations With Patented Stackable Guide Wires

CoreLink also announced the company has been awarded patent number 11,052,229 by the United States Patent and Trademark Office (USPTO). The patent, titled, “Devices and methods for guidewire extension in spinal surgery,” expands the company’s intellectual property portfolio. These unique stackable guide wires are designed to give surgeons streamlined instruments and constant proximal control during every step of these lateral SI joint fusion procedures.

With the spine market expected to increase 5 percent this year1 and sacroiliac joint fusion growing up to 14.7 percent2, SI joint fusion continues to be an exciting new area of spine surgery. Lower back pain is one of the most common reasons for a physician visit and those experiencing pain attributable to the SI joint range from 15 to 30 percent3.

Entasis is designed for minimally invasive SI joint fusion procedures. The system provides an array of joint stabilizing compression screw options in three diameters and nine length options, enabling surgeons to precisely fit varying patient anatomies. The screws feature circumferential fenestrations that self-harvest bone graft while compressing the joint. Dual leads threads ease insertion and easy-out threaded removal tools are available, if needed. These innovative features and stackable guide wire have led to the Entasis system being recognized as a top 10 sacroiliac joint fusion system by SPINEMarketGroup. A full suite of resources to assist in surgeon training, patient education, and patient workup is also available.

“CoreLink is proud to be a leader in the SI fusion market as a result of our strong product offering and vast training resources,” said Jay Bartling, CEO, CoreLink. “Every step of our process, from design to manufacturing, keeps surgeon ease of use and patient outcomes top of mind. This is evident in our SI joint fusion systems with patented technology, unique compression screw design, and comprehensive offerings.”

CoreLink will be exhibiting at the North American Spine Society’s annual meeting in Boston, September 29 through October 2, booth #3221, where a full display of surgical systems will be featured, including Entasis.


References

1.

The Spine Market Group. (2021). What is the Spine Market First Estimate for 2021. Retrieved from http://thespinemarketgroup.com/which-is-the-spine-market-first-estimate-for-2021.

2.

360 Research Reports. (2020). Global MIS Sacroiliac Joint Fusion Sales Market Report 2020. Retrieved from https://www.360researchreports.com/global-mis-sacroiliac-joint-fusion-sales-market-16695557.

3.

Martin, C. T., Haase, L., Lender, P. A., & Polly, D. W. (2020). Minimally Invasive Sacroiliac Joint Fusion: The Current Evidence. International journal of spine surgery, 14(Suppl 1), 20–29. https://doi.org/10.14444/6072

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy